49 results about "Growth factor receptor" patented technology

The present invention relates to agents for in vivo imaging and detection of platelet-derived growth factor receptor alpha (PDGFR alpha)-expressing cancers using oxiracemab antibodies and methods of use thereof, including methods for imaging cancer and methods for selecting a patient for treatment.

The present application belongs to the field of biomedical technology, and particularly relates to an axial length and growth trend evaluation method of eye axis based on PDGFRA gene and a PDGFRA enzyme activity control agent. The method comprises the following steps: 1) collecting an eye biological sample of a subject; 2) based on the expression level of PDGFRA gene of platelet-derived growth factor receptor alpha in the collected biological sample; 3) based on the expression level, calculating the axial length of the eye axis according to the quantitative relationship between the expression amount of PDGFRA and the axial length of the eye axis, and predicting the growth trend of the axial length of the eye axis through additional calculation. The technical scheme of the present application can effectively detect and evaluate the axial length of the eye axis, effectively judge the growth trend of the axial length of the eye axis, and directly and efficiently control the axial length of the eye axis and its growth trend through the existing drug components.

The present invention relates to a novel heterocyclic compound which is a compound having FGFR protein activity. Specifically, the invention relates to a compound shown as a formula (II), or pharmaceutically acceptable salt, solvate, polymorphic substance or isomer thereof, and application of the compound in preparation of medicines for treating diseases related to FGFR (Factor Growth Factor Receptor).

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

Modified natural killer (NK) cells or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express thrombopoietin receptors, erythropoietin receptors, or chimeric peptides comprising an extracellular domain, a transmembrane domain, and an intracellular domain including an intracellular signaling domain of an interleukin receptor. Methods for treating cancer subjects are also provided, comprising administering modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or an erythropoietin receptor agonist, and in some instances, in combination with interleukin-2, particularly reduced or low doses of IL-2.

The present invention relates to a composition comprising an olaratumab antibody conjugated to a therapeutic radioisotope for the treatment of cancer expressing platelet-derived growth factor receptor alpha (PDGFR-alpha), and to a method of using the same.

The present invention belongs to the technical fields of biomedicine and molecular biology, and particularly relates to a single-chain fragment variable (scFv) targeting human platelet-derived growth factor receptor (PDGFR)-β and use thereof in chimeric antigen receptor (CAR)-T cell immunotherapy. In the present invention, a scFv sequence targeting a human-derived PDGFRβ antigen is first obtained by immunizing a mouse, and then a second-generation CAR is constructed based on this, and additionally a CAR-T cell is obtained via lentivirus infection. The CAR-T cell can effectively kill a PDGFRβ antigen-positive 293T cell. The present invention provides a brand-new idea for eliminating PDGFRβ-positive cells to treat chronic kidney diseases, chronic liver diseases, cardiovascular diseases and various tumor diseases including various organ fibrosis, and has extremely attractive further development value and application prospects.

The invention relates to an application of osimertinib combined with chidamide in treatment of osimertinib drug-resistant lung cancer, and particularly relates to the following aspects: (1) osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and shows a remarkable curative effect in treatment of non-small cell lung cancer (NSCLC) patients carrying specific EGFR mutation; (2) chidamide is a novel oral HDACi, can induce cell apoptosis, cell cycle arrest and cell growth inhibition, and shows good tolerance and antitumor activity in various cancer types; and (3) chidamide is taken as an epigenetic regulating agent and can be in synergistic effect with osimertinib, so that the capability of killing lung cancer cells is enhanced. The invention belongs to the technical field of medicines, and particularly provides application of osimertinib combined with chidamide in treatment of osimertinib drug-resistant lung cancer.

The present invention relates to a polynucleotide molecule comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) or fragment thereof, said chimeric antigen receptor (CAR) or fragment thereof i) comprising an extracellular domain comprising an antigen binding region that binds to epidermal growth factor receptor variant III (EGFRvIII); or ii) comprising an extracellular domain comprising an antigen binding region that binds to CD19; wherein the nucleotide sequence encoding the CAR is operably linked to a promoter, and wherein the polynucleotide molecule further comprises a nucleotide sequence encoding a heterologous signal peptide fused to a signal regulatory protein gamma (SIRPy)-related protein (SGRP). The present invention further relates to a chimeric antigen receptor (CAR)-T cell expressing the polynucleotide molecule, as well as a method of treating cancer using said polynucleotide molecule and / or a chimeric antigen receptor (CAR)-T cell expressing said polynucleotide molecule.

Modified platelet-derived growth factor receptor alpha (PDGFRα) polypeptides are described. The modified polypeptides include at least one amino acid substitution that allows the polypeptide to retain the capacity to bind a cytomegalovirus (CMV) trimer comprised of glycoprotein H (gH), gL and gO, but leads to reduced binding to one or more platelet-derived growth factor (PDGF) ligands. Use of the modified PDGFRα polypeptides for inhibiting CMV replication and / or spread, or treating a CMV infection, is also described.

The present invention provides an antitumor agent for treating a patient with a malignant tumor expressing EGFR who has at least one mutation selected from the group consisting of the L718X mutation in exon 18 and the L792X mutation in exon 20, wherein X represents an arbitrary amino acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.

The invention relates to an application of an SNP (Single Nucleotide Polymorphism) labeled primer pair in a porcine GFRA1 (Growth Factor Receptor 1) gene coding region in resisting mycoplasma pneumonia traits. The locus of the SNP marker is a molecular marker of the rs329759240 nucleotide locus of a pig GFRA1 gene coding region in a reference sequence of an international pig genome version 11.1, and the SNP marker has A / G polymorphism. According to a primer pair for detecting the SNP marker, an upstream primer is SEQ ID NO: 2, and a downstream primer is SEQ ID NO: 3. The SNP marker provided by the invention can be applied to marker-assisted selection of swine mycoplasmal pneumonia resistant traits, and swine populations or strains resistant to swine mycoplasmal pneumonia traits are screened by identifying the genotype of the SNP marker. Establishment of the group or strain can improve the capability of tolerating swine mycoplasmal pneumonia and produce more social and economic benefits.

The invention discloses an antibody for detecting a soluble platelet-derived growth factor receptor beta, a kit and application. The antibody is prepared by coupling a soluble platelet-derived growth factor receptor beta-specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the soluble platelet-derived growth factor receptor beta-specific antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The antibody can specifically detect the soluble platelet-derived growth factor receptor beta, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or illness monitoring of blood-brain barrier dysfunction related diseases, the kit has good sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of related diseases, and has important significance and clinical application value.

This disclosure relates to an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) and an anti-EGFR / cMET antibody molecule for use in combination in the treatment of cancer (for example, non-small cell lung cancer [NSCLC]).

Methods of treating a cancer expressing an epidermal growth factor receptor (EGFR) or expressing a hepatocyte growth factor receptor (c-Met) in a subject in need thereof are provided. These methods comprise administering to a subject a therapy comprising an isolated bispecific anti-EGFR / c-Met antibody wherein a dose comprising about 1400 mg to 2100 mg is administered once every 21 day cycle.

The present disclosure provides a pharmaceutical association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one adhesion protein inhibitor which inhibits at least one transmembrane cell adhesion protein of said neoplastic cell.

The present invention relates to a compound capable of preventing or treating lung cancer by inhibiting the expression or activity of Anoctamin 1 (ANO1), which is a calcium-activated chloride channel, and epidermal growth factor receptor (EGFR), which is an epithelial growth factor receptor. The compound of the present invention can be advantageously used alone as a composition for preventing or treating lung cancer, can be used per se as a dual-target anticancer drug for ANO1 and EGFR, and can also be used as an adjuvant or a combination preparation in combination with an EGFR-targeted therapeutic agent.

The invention discloses an application of melanine in preparation of an antitumor drug. The invention proposes and verifies that the melanine can significantly inhibit the cell proliferation activity of the epidermal growth factor receptor mutant non-small cell lung cancer by inducing ferroptosis for the first time, and significantly inhibit the migration and diffusion of cancer cells and the colony proliferation and tumorigenesis potential of the cancer cells; and a new choice and direction are provided for clinical treatment of the epidermal growth factor receptor mutant non-small cell lung cancer.

The application discloses a compound with a general formula (I), a pharmaceutically acceptable salt, a hydrate or a prodrug of the compound, and application of the compound in preparation of a medicine for preventing and / or treating diseases mediated by tyrosine kinase and / or histone deacetylase. The compound can simultaneously produce a good inhibiting effect on multiple targets (especially histone deacetylase 1, histone deacetylase 6 and two tyrosine kinases (vascular endothelial cell growth factor receptor and platelet-derived growth factor receptor)), and is expected to be used in treatment of malignant tumors.

The present invention relates to reagents for in vivo imaging and detection of cancer expressing platelet-derived growth factor receptor alpha (PDGFR alpha), as well as methods for imaging cancer and methods for selecting patients for treatment, including methods for using the same.

The invention discloses an application of a near-infrared fluorescent probe in preparation of a near-infrared first region and near-infrared second region diagnosis, prevention and / or treatment medicine, and belongs to the technical field of organic fluorescent molecules. The near-infrared fluorescent probe specifically targets a skin growth factor receptor (EGFR), has good near-infrared first-region and second-region capabilities, can be developed for in vivo diagnosis, can also be used for intraoperative positioning, can be applied to operations such as fluorescent near-infrared first-region and second-region guided tumor and the like, has a certain clinical application prospect, and has a wide application prospect. The method is applied to clinical near-infrared first-zone and second-zone intraoperative navigation.

A recombinant Clever-1 fragment and a method for producing a recombinant Clever-1 fragment, which fragment mimicking a secreted form of Clever-1 (sClever-1) enriched in plasma of cancer patients, and has observed to have T cell-binding activity and is capable of binding to insulin-like growth factor 2 receptor (IGF2R) By its mechanism of action, a recombinant Clever-1 fragment of the present invention is suitable for use in a treatment of inflammation and / or autoimmune diseases.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

The invention relates to quinazolinone-derived compounds that show anticancer activity on the adenocarcinoma human alveolar basal epithelial cell line (A549) by inducing apoptosis in lung cancer cells through inhibition of the epidermal growth factor receptor (EGFR), and at the same time do not have any cytotoxic effects on healthy cells, and to the synthesis methods of these compounds The general structure of the compounds of the invention is shown by Formula (X).

Described herein are polypeptides comprising an FGF17, IGF2, or BMP7 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Also described herein are synergistic combinations of a Fibroblast Growth Factor Receptor agonist and a glycosaminoglycan, an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid, and BMP receptor agonists and mTOR activators and / or glycosaminoglycans. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and / or synergistic compositions.

Disclosed is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the recombinant protein is capable of binding PD-L1, VEGF and Fc receptor simultaneously. Also disclosed are a recombinant antibody containing two recombinant proteins of the disclosure, a polynucleotide encoding the recombinant protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of VEGF and / or PD-L1 using the recombinant protein.

The present application discloses a chemical entity of formula (I) (or a pharmaceutically acceptable salt and / or hydrate and / or co-crystal and / or pharmaceutical combination thereof) that inhibits epidermal growth factor receptor (EGFR, ERBB1) and / or human epidermal growth factor receptor 2 (HER2, ERBB2). The compounds of formula (I) may be used, for example, to treat a condition, disease or disorder (e.g., cancer) in a subject (e.g., a human) wherein increased (e.g., excessive) EGFR and / or HER2 activation promotes the pathology and / or symptom and / or progression of the condition, disease or disorder. Also provided are compositions comprising the chemical entities as well as methods of using and making the chemical entities. (I)

The present invention aims to provide an arthritis treatment agent containing synovial membrane-derived mesenchymal stem cells having molecules essential for joint treatment, and a method for producing the arthritis treatment agent. [Solution] According to the present invention, an arthritis treatment agent is provided which comprises synovial mesenchymal stem cells having one or more surface antigens, either integrin β1 or platelet-derived growth factor receptor β.

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for the translation of a target biomolecule, such as platelet-derived growth factor receptor beta (PDGFRB). The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.